Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
Immune checkpoint inhibitors with or without chemotherapy are now standard of care for non-small cell lung cancer. However, the benefits of combination vs sequential therapy have not been fully explored. Here, the authors analysed 1,133 patient records and show combination therapy showed increased p...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-36328-z |
| _version_ | 1811165858045624320 |
|---|---|
| author | Lingzhi Hong Muhammad Aminu Shenduo Li Xuetao Lu Milena Petranovic Maliazurina B. Saad Pingjun Chen Kang Qin Susan Varghese Waree Rinsurongkawong Vadeerat Rinsurongkawong Amy Spelman Yasir Y. Elamin Marcelo V. Negrao Ferdinandos Skoulidis Carl M. Gay Tina Cascone Saumil J. Gandhi Steven H. Lin Percy P. Lee Brett W. Carter Carol C. Wu Mara B. Antonoff Boris Sepesi Jeff Lewis Don L. Gibbons Ara A. Vaporciyan Xiuning Le J. Jack Lee Sinchita Roy-Chowdhuri Mark J. Routbort Justin F. Gainor John V. Heymach Yanyan Lou Jia Wu Jianjun Zhang Natalie I. Vokes |
| author_facet | Lingzhi Hong Muhammad Aminu Shenduo Li Xuetao Lu Milena Petranovic Maliazurina B. Saad Pingjun Chen Kang Qin Susan Varghese Waree Rinsurongkawong Vadeerat Rinsurongkawong Amy Spelman Yasir Y. Elamin Marcelo V. Negrao Ferdinandos Skoulidis Carl M. Gay Tina Cascone Saumil J. Gandhi Steven H. Lin Percy P. Lee Brett W. Carter Carol C. Wu Mara B. Antonoff Boris Sepesi Jeff Lewis Don L. Gibbons Ara A. Vaporciyan Xiuning Le J. Jack Lee Sinchita Roy-Chowdhuri Mark J. Routbort Justin F. Gainor John V. Heymach Yanyan Lou Jia Wu Jianjun Zhang Natalie I. Vokes |
| author_sort | Lingzhi Hong |
| collection | DOAJ |
| description | Immune checkpoint inhibitors with or without chemotherapy are now standard of care for non-small cell lung cancer. However, the benefits of combination vs sequential therapy have not been fully explored. Here, the authors analysed 1,133 patient records and show combination therapy showed increased protection against early progression, but similar overall survival. |
| first_indexed | 2024-04-10T15:43:20Z |
| format | Article |
| id | doaj.art-8e4eb1b2cf4847c68859d771395453bd |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-10T15:43:20Z |
| publishDate | 2023-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-8e4eb1b2cf4847c68859d771395453bd2023-02-12T12:16:38ZengNature PortfolioNature Communications2041-17232023-02-0114111510.1038/s41467-023-36328-zEfficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong0Muhammad Aminu1Shenduo Li2Xuetao Lu3Milena Petranovic4Maliazurina B. Saad5Pingjun Chen6Kang Qin7Susan Varghese8Waree Rinsurongkawong9Vadeerat Rinsurongkawong10Amy Spelman11Yasir Y. Elamin12Marcelo V. Negrao13Ferdinandos Skoulidis14Carl M. Gay15Tina Cascone16Saumil J. Gandhi17Steven H. Lin18Percy P. Lee19Brett W. Carter20Carol C. Wu21Mara B. Antonoff22Boris Sepesi23Jeff Lewis24Don L. Gibbons25Ara A. Vaporciyan26Xiuning Le27J. Jack Lee28Sinchita Roy-Chowdhuri29Mark J. Routbort30Justin F. Gainor31John V. Heymach32Yanyan Lou33Jia Wu34Jianjun Zhang35Natalie I. Vokes36Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Imaging Physics, The University of Texas MD Anderson Cancer CenterDivision of Hematology and Oncology, Mayo ClinicDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Radiology, Massachusetts General HospitalDepartment of Imaging Physics, The University of Texas MD Anderson Cancer CenterDepartment of Imaging Physics, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Pathology, The University of Texas MD Anderson Cancer CenterDepartment of Pathology, The University of Texas MD Anderson Cancer CenterDepartment of Medicine, Massachusetts General HospitalDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDivision of Hematology and Oncology, Mayo ClinicDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer CenterImmune checkpoint inhibitors with or without chemotherapy are now standard of care for non-small cell lung cancer. However, the benefits of combination vs sequential therapy have not been fully explored. Here, the authors analysed 1,133 patient records and show combination therapy showed increased protection against early progression, but similar overall survival.https://doi.org/10.1038/s41467-023-36328-z |
| spellingShingle | Lingzhi Hong Muhammad Aminu Shenduo Li Xuetao Lu Milena Petranovic Maliazurina B. Saad Pingjun Chen Kang Qin Susan Varghese Waree Rinsurongkawong Vadeerat Rinsurongkawong Amy Spelman Yasir Y. Elamin Marcelo V. Negrao Ferdinandos Skoulidis Carl M. Gay Tina Cascone Saumil J. Gandhi Steven H. Lin Percy P. Lee Brett W. Carter Carol C. Wu Mara B. Antonoff Boris Sepesi Jeff Lewis Don L. Gibbons Ara A. Vaporciyan Xiuning Le J. Jack Lee Sinchita Roy-Chowdhuri Mark J. Routbort Justin F. Gainor John V. Heymach Yanyan Lou Jia Wu Jianjun Zhang Natalie I. Vokes Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer Nature Communications |
| title | Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer |
| title_full | Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer |
| title_fullStr | Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer |
| title_full_unstemmed | Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer |
| title_short | Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer |
| title_sort | efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non small cell lung cancer |
| url | https://doi.org/10.1038/s41467-023-36328-z |
| work_keys_str_mv | AT lingzhihong efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT muhammadaminu efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT shenduoli efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT xuetaolu efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT milenapetranovic efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT maliazurinabsaad efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT pingjunchen efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT kangqin efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT susanvarghese efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT wareerinsurongkawong efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT vadeeratrinsurongkawong efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT amyspelman efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT yasiryelamin efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT marcelovnegrao efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT ferdinandosskoulidis efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT carlmgay efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT tinacascone efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT saumiljgandhi efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT stevenhlin efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT percyplee efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT brettwcarter efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT carolcwu efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT marabantonoff efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT borissepesi efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT jefflewis efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT donlgibbons efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT araavaporciyan efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT xiuningle efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT jjacklee efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT sinchitaroychowdhuri efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT markjroutbort efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT justinfgainor efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT johnvheymach efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT yanyanlou efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT jiawu efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT jianjunzhang efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer AT natalieivokes efficacyandclinicogenomiccorrelatesofresponsetoimmunecheckpointinhibitorsaloneorwithchemotherapyinnonsmallcelllungcancer |